PRE vs. HBIO, SEER, AKYA, BNGO, RPID, AXDX, OMIC, TLIS, ASTC, and HLTH
Should you be buying Prenetics Global stock or one of its competitors? The main competitors of Prenetics Global include Harvard Bioscience (HBIO), Seer (SEER), Akoya Biosciences (AKYA), Bionano Genomics (BNGO), Rapid Micro Biosystems (RPID), Accelerate Diagnostics (AXDX), Singular Genomics Systems (OMIC), Talis Biomedical (TLIS), Astrotech (ASTC), and Cue Health (HLTH). These companies are all part of the "analytical instruments" industry.
Prenetics Global (NASDAQ:PRE) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.
Harvard Bioscience has a net margin of -8.18% compared to Prenetics Global's net margin of -193.60%. Harvard Bioscience's return on equity of 0.26% beat Prenetics Global's return on equity.
In the previous week, Harvard Bioscience had 11 more articles in the media than Prenetics Global. MarketBeat recorded 14 mentions for Harvard Bioscience and 3 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 1.54 beat Harvard Bioscience's score of 0.15 indicating that Prenetics Global is being referred to more favorably in the media.
Harvard Bioscience has higher revenue and earnings than Prenetics Global. Harvard Bioscience is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.
25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 7.8% of Prenetics Global shares are held by insiders. Comparatively, 9.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Prenetics Global has a beta of -0.28, suggesting that its stock price is 128% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Prenetics Global presently has a consensus target price of $9.00, indicating a potential upside of 50.25%. Given Prenetics Global's higher possible upside, equities research analysts plainly believe Prenetics Global is more favorable than Harvard Bioscience.
Harvard Bioscience received 363 more outperform votes than Prenetics Global when rated by MarketBeat users. However, 83.33% of users gave Prenetics Global an outperform vote while only 72.02% of users gave Harvard Bioscience an outperform vote.
Summary
Harvard Bioscience beats Prenetics Global on 11 of the 17 factors compared between the two stocks.
Get Prenetics Global News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prenetics Global Competitors List
Related Companies and Tools
